Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

AIMS: To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin 9, compared with ezetimibe, as add-on therapy to maximally tolerated statin therapy in high cardiovascular risk p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cannon, Christopher P., Cariou, Bertrand, Blom, Dirk, McKenney, James M., Lorenzato, Christelle, Pordy, Robert, Chaudhari, Umesh, Colhoun, Helen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
FASTTrack Clinical Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430683/
https://www.ncbi.nlm.nih.gov/pubmed/25687353
http://dx.doi.org/10.1093/eurheartj/ehv028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430683/
https://www.ncbi.nlm.nih.gov/pubmed/25687353
http://dx.doi.org/10.1093/eurheartj/ehv028

Ejemplares similares